ANDREWS DEBORAH J 4

What Happened
Deborah J. Andrews, a director of Lineage Cell Therapeutics, was granted 125,000 shares as an equity award (transaction code A) on July 1, 2026. The Form 4 reports an acquisition price of $0.00 per share (total reported value $0), indicating a derivative equity award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (timely filing).
• Award: 125,000 shares, $0.00 per share (reported acquisition value $0).
• Vesting: Will vest and become exercisable on the earlier of July 1, 2027 and the issuer’s next annual shareholders meeting, subject to Andrews’ continuous service (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• Transaction type: Derivative award (A). No 10b5-1 plan, tax‑withholding, or late‑filing flags noted in the provided info.

Context
This was a compensation/retention award, not a market purchase or sale; such grants are common for directors and do not necessarily signal immediate buying or selling intent. The vesting condition ties the award to continued service and a time/meeting milestone, meaning the shares aren’t immediately free trading unless other terms apply.